In the Phase Ib study, SPX-001 will be given through a nebuliser to assess its safety and efficacy in healthy participants infected with influenza. Credit: Sincerely Media on Unsplash.

Healthcare and pharmaceutical firm SpectrumX has announced that it is prepared to proceed with the clinical development of SPX-001, its respiratory drug candidate.

The latest move comes after the company’s constructive scientific advice meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) earlier this month.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Next month, the company plans to submit a combined clinical trial and ethics committee application to the MHRA for a placebo-controlled Phase Ib influenza viral challenge study of its respiratory drug candidate in healthy participants.

If approved, the Phase Ib study will be the first in-human trial to give SPX-001 through a nebuliser for evaluating its safety and efficacy, compared to a placebo, in healthy participants who are infected with influenza.

SpectrumX CEO Damien Hancox said: “We believe SPX-001 could be a significant new weapon in the fight against viral respiratory infections, and this is a critical milestone in progressing our drug candidate toward targeted market authorisation approval.

See Also:

“We would like to thank the MHRA for their helpful guidance and responses to our initial proposal to begin human clinical trials, and we hope this brings us another step closer to trialling what we believe is a revolutionary treatment for respiratory infections.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to further conduct trials in respiratory infection patients after the successful completion of the planned Phase Ib trial.

This will help collect additional data that is required to seek market authorisation approval.

SpectrumX’s nebulised respiratory infection drug candidate, SPX-001, has been developed based on the company’s licensed hypochlorous acid (HOCl)-based SPC-069 drug.